Iovance Biotherapeutics Target Price

Where could IOVA trade next? Consensus target price: $7.8.

Get informed when a big investor buys or sells

+ Follow

Share Price

$8.6

Average Target Price

$7.83

8.9% downside

6 analysts in the last 4 months

High: $13 | Low: $5

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-08-20	UBSDavid Dai	$7	18.6% downside
2026-08-18	Mizuho Securities	$11	27.9% upside
2026-08-07	Robert W. BairdCollen Kusy	$6	30.2% downside
2026-08-07	Barclays	$13	51.2% upside
2026-06-01	Wells Fargo	$5	41.9% downside
2026-06-01	National Bank	$5	41.9% downside
2026-02-05	Goldman SachsAndrea Newkirk	$2	76.7% downside
2025-05-16	UBSDavid Dai	$2	76.7% downside
2025-02-28	Piper Sandler	$6	30.2% downside
2025-01-31	Piper SandlerJoseph Catanzaro	$7.5	12.8% downside
2024-10-24	UBSDavid Dai	$17	97.7% upside
2024-08-09	Stifel NicolausBenjamin Burnett	$11.5	33.7% upside
2024-08-09	Robert W. BairdColleen Kusy	$12	39.5% upside
2024-07-29	Piper SandlerJoseph Catanzaro	$10	16.3% upside
2024-06-20	JMP SecuritiesReni Benjamin	$11.5	33.7% upside
2024-05-31	Stifel NicolausBenjamin Burnett	$14	62.8% upside
2024-03-14	Piper SandlerJoseph Catanzaro	$19	120.9% upside
2022-12-08	Goldman SachsMadhu Kumar	$6	30.2% downside
2022-11-20	Piper SandlerJoseph Catanzaro	$11	27.9% upside
2022-08-23	Robert W. BairdMichael Ulz	$12.5	45.3% upside
2022-07-01	Goldman Sachs	$18	109.3% upside
2022-05-27	Stifel Nicolaus	$13	51.2% upside
2022-04-07	Robert W. BairdColleen Kusy	$34	295.3% upside
2022-04-05	Robert W. BairdColleen M. Kusy	$30	248.8% upside
2022-01-28	Stifel NicolausBenjamin Burnett	$25	190.7% upside
2022-01-05	Wells FargoNick Abbott	$25	190.7% upside
2021-05-19	BarclaysPeter Lawson	$40	365.1% upside

Iovance Biotherapeutics (IOVA) FAQ

Iovance Biotherapeutics posts a target price of $7.8. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $7.8 for IOVA means covering analysts, on average, see the stock 8.9% downside of $8.6 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for IOVA's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Iovance Biotherapeutics's other metric pages and overview cover the third.

Judging Iovance Biotherapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $7.8 here, then scan peer and history charts to see if the gap is persistent.